Keros Therapeutics, Inc.
KROS
$14.91
$0.151.02%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 85,820.30% | 91,657.69% | 2,250.99% | 8,037.50% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 85,820.30% | 91,657.69% | 2,250.99% | 8,037.50% | -- |
| Cost of Revenue | -11.28% | 45.82% | -- | -75.35% | -86.17% |
| Gross Profit | 1,574.79% | 3,046.23% | 2,250.99% | 75.88% | 86.42% |
| SG&A Expenses | 18.02% | 9.58% | 16.99% | 19.41% | 25.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.08% | 25.16% | 26.04% | 31.67% | 34.81% |
| Operating Income | 100.17% | 94.26% | -24.06% | -31.26% | -34.62% |
| Income Before Tax | 116.00% | 109.08% | -22.26% | -27.45% | -32.81% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 111.17% | 102.63% | -22.46% | -27.45% | -32.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 111.17% | 102.63% | -22.46% | -27.45% | -32.81% |
| EBIT | 100.17% | 94.26% | -24.06% | -31.26% | -34.62% |
| EBITDA | 100.89% | 94.95% | -23.93% | -31.11% | -34.46% |
| EPS Basic | 106.91% | 97.21% | 3.52% | -5.26% | -13.01% |
| Normalized Basic EPS | 110.82% | 102.17% | 3.66% | -5.27% | -13.01% |
| EPS Diluted | 82.97% | 75.38% | 1.55% | -5.45% | -42.37% |
| Normalized Diluted EPS | 109.96% | 101.32% | 3.66% | -5.27% | -13.01% |
| Average Basic Shares Outstanding | 20.91% | 23.59% | 27.13% | 21.34% | 18.71% |
| Average Diluted Shares Outstanding | 21.26% | 23.96% | 27.13% | 21.34% | 18.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |